|
1
|
Merz M, Neben K, Raab MS, Sauer S, Egerer
G, Hundemer M, Hose D, Kunz C, Heiß C, Ho AD, et al: Hillengass
Autologous stem cell transplantation for elderly patients with
newly diagnosed multiple myeloma in the era of novel agents. Ann
Oncol. 25:189–195. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ludwig H, Avet-Loiseau H, Bladé J,
Boccadoro M, Cavenagh J, Cavo M, Davies F, de la Rubia J, Delimpasi
S, Dimopoulos M, et al: European perspective on multiple myeloma
treatment strategies: Update following recent congresses.
Oncologist. 17:592–606. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ludwig H, Miguel JS, Dimopoulos MA,
Palumbo A, Sanz R Garcia, Powles R, Lentzsch S, Chen W Ming, Hou J,
Jurczyszyn A, et al: Durie International myeloma working group
recommendations for global myeloma care. Leukemia. 28:981–992.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pulte D, Gondos A and Brenner H:
Improvement in survival of older adults with multiple myeloma:
Results of an updated period analysis of SEER data. Oncologist.
16:1600–1603. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Brenner H, Gondos A and Pulte D: Recent
major improvement in long-term survival of younger patients with
multiple myeloma. Blood. 111:2521–2526. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Klein B, Seckinger A, Moehler T and Hose
D: Molecular pathogenesis of multiple myeloma: Chromosomal
aberrations, changes in gene expression, cytokine networks, and the
bone marrow microenvironment. Recent Results Cancer Res. 183:39–86.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Engelhardt M, Terpos E, Kleber M, Gay F,
Wäsch R, Morgan G, Cavo M, van de Donk N, Beilhack A, Bruno B, et
al: European myeloma network recommendations on the evaluation and
treatment of newly diagnosed patients with multiple myeloma.
Haematologica. 99:232–242. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gaultney JG, Redekop WK, Sonneveld P and
Uyl-de Groot CA: Novel anticancer agents for multiple myeloma: A
review of the evidence for their therapeutic and economic value.
Expert Rev Anticancer Ther. 12:839–854. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Knauf W, Kellermann L, Poenisch W, Einsele
H, Straka C, Frohn C and Goldschmidt H: How to treat multiple
myeloma - a representative multicentre treatment survey. Onkologie.
33:604–610. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Durie BG and Salmon SE: A clinical staging
system for multiple myeloma. Correlation of measured myeloma cell
mass with presenting clinical features, response to treatment, and
survival. Cancer. 36:842–854. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Greipp PR, San Miguel J, Durie BGM,
Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child A, Avet-Loiseau
H, Kyle RA, et al: International staging system for multiple
myeloma. J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Moreau P, Cavo M, Sonneveld P, Rosinol L,
Attal M, Pezzi A, Goldschmidt H, Lahuerta JJ, Marit G, Palumbo A,
et al: Combination of international scoring system 3, high lactate
dehydrogenase and t (4;14) and/or del (17p) identifies patients
with multiple myeloma (MM) treated with front-line autologous
stem-cell transplantation at high risk of early MM
progression-related death. J Clin Oncol. 32:2173–2180. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fermand JP, Ravaud P, Chevret S, Divine M,
Leblond V, Belanger C, Macro M, Pertuiset E, Dreyfus F, Mariette X,
et al: High-dose therapy and autologous peripheral blood stem cell
transplantation in multiple myeloma: Up-front or rescue treatment?
Results of a multicenter sequential randomized clinical trial.
Blood. 92:3131–3136. 1998.PubMed/NCBI
|
|
14
|
van Rhee F, Giralt S and Barlogie B: The
future of autologous stem cell transplantation in myeloma. Blood.
124:328–333. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fermand JP, Katsahian S, Divine M, Leblond
V, Dreyfus F, Macro M, Arnulf B, Royer B, Mariette X, Pertuiset E,
et al: High-dose therapy and autologous blood stem-cell
transplantation compared with conventional treatment in myeloma
patients aged 55 to 65 years: Long-term results of a randomized
control trial from the Group Myelome-Autogreffe. J Clin Oncol.
23:9227–9233. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Palumbo A, Cavallo F, Gay F, Di Raimondo
F, Ben Yehuda D, Petrucci MT, Pezzatti S, Caravita T, Cerrato C,
Ribakovsky E, et al: Autologous transplantation and maintenance
therapy in multiple myeloma. N Engl J Med. 371:895–905. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ludwig H, Beksac M, Bladé J, Boccadoro M,
Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, et
al: Current multiple myeloma treatment strategies with novel
agents: A European perspective. Oncologist. 15:6–25. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sonneveld P, Schmidt-Wolf IG, van der Holt
B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E,
Broyl A, Blau IW, et al: Bortezomib induction and maintenance
treatment in patients with newly diagnosed multiple myeloma:
Results of the randomized phase III HOVON-65/ GMMG-HD4 trial. J
Clin Oncol. 30:2946–2955. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Palumbo A, Hajek R, Delforge M, Kropff M,
Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W,
Zodelava M, Weisel K, et al: Continuous lenalidomide treatment for
newly diagnosed multiple myeloma. N Engl J Med. 366:1759–1769.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
McCarthy PL, Owzar K, Hofmeister CC, Hurd
DD, Hassoun H, Richardson PG, Giralt S, Stadtmauer EA, Weisdorf DJ,
Vij R, et al: Lenalidomide after stem-cell transplantation for
multiple myeloma. N Engl J Med. 366:1770–1781. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Palumbo A, Bringhen S, Kumar SK,
Lupparelli G, Usmani S, Waage A, Larocca A, van der Holt B, Musto
P, Offidani M, et al: Second primary malignancies with lenalidomide
therapy for newly diagnosed myeloma: A meta-analysis of individual
patient data. Lancet Oncol. 15:333–342. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sellner L, Heiss C, Benner A, Raab MS,
Hillengass J, Hose D, Lehners N, Egerer G, Ho AD, Goldschmidt H and
Neben K: Autologous retransplantation for patients with recurrent
multiple myeloma: A single-center experience with 200 patients.
Cancer. 119:2438–2446. 2013. View Article : Google Scholar : PubMed/NCBI
|
